Panbela Announces Issuance of New Patent in Japan; Patent is for Claims of a Novel Process for the Production of SBP-101GlobeNewsWire • 03/22/23
Panbela Provides Business Update and Reports Q4 and FY 2022 Financial ResultsGlobeNewsWire • 03/16/23
Panbela to Host Fourth Quarter and Year End 2022 Earnings Conference Call on March 16, 2023GlobeNewsWire • 03/08/23
Panbela Announces First Patient Enrolled in South Korea for ASPIRE Trial Studying Ivospemin (SBP-101) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal AdenocarcinomaGlobeNewsWire • 03/07/23
Acceptance of SBP-101 Abstract for Poster Presentation at American Association for Cancer Research (AACR)GlobeNewsWire • 03/01/23
Panbela Announces Closing of Approximately $15 Million Public Offering, and Regains Compliance with Nasdaq Listing StandardsGlobeNewsWire • 02/13/23
Panbela Announces Adoption of Commission Implementing Decision from the EMA for the Orphan Designation of Ivospemin (SBP-101) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal AdenocarcinomaGlobeNewsWire • 01/19/23
Panbela Starts Phase II Trial of CPP-1X-T for Recent Onset Type I Diabetes, in Collaboration with Indiana University School of Medicine and JDRFGlobeNewsWire • 01/11/23
Panbela Receives Positive EMA Opinion on Orphan Designation for Ivospemin (SBP-101) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal AdenocarcinomaGlobeNewsWire • 12/14/22
Panbela Announces First Patients Enrolled in Europe for ASPIRE Trial Studying Ivospemin (SBP-101) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal AdenocarcinomaGlobeNewsWire • 11/28/22
Panbela Schedules Conference Call on, November 10, 2022, to Report 2022 Third Quarter Financial ResultsGlobeNewsWire • 10/31/22
Panbela to Participate in the Roth Inaugural Healthcare Opportunities ConferenceGlobeNewsWire • 10/06/22
Panbela Receives Approvals to Open Trial Sites in Spain, France and Italy for ASPIRE Trial Studying Ivospemin (SBP-101) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal AdenocarcinomaGlobeNewsWire • 09/29/22
Panbela Therapeutics, Inc.'s (PBLA) CEO Jennifer Simpson on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/15/22
Panbela Announces First Patient Enrolled in its Aspire Trial Studying SBP-101 in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal AdenocarcinomaGlobeNewsWire • 08/11/22
Panbela Expands Aspire Trial to Australia, Studying SBP-101 in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal AdenocarcinomaGlobeNewsWire • 08/04/22
Panbela Schedules Conference Call on, August 15, 2022, to Report 2022 Second Quarter Financial ResultsGlobeNewsWire • 08/01/22
Panbela Announces Publication of Preclinical Data Titled: Expanded Potential of the Polyamine Analogue SBP-101 (Diethyl Dihydroxyhomospermine) as a Modulator of Polyamine Metabolism and Cancer TherapeuticGlobeNewsWire • 06/28/22
